News Image

Top movers in Thursday's pre-market session

By Mill Chart

Last update: Sep 22, 2022

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

Pre-market gainers

TickerChangeComment
SPRO151.0%SPERO THERAPEUTICS INC's (NASDAQ:SPRO) stock price increased by 151.0% to $2.06. The stock is trading 89.92% lower than 6 months ago.
MOHO39.51%ECMOHO LTD's (NASDAQ:MOHO) shares rose 39.51% to $0.24 during Thursday's pre-market session. This is a continuation of yesterday's gain of 50.73%.
AVCTW28.38%PENSARE ACQUISITION CORP-CW's (NASDAQ:AVCTW) stock price increased by 28.38% to $0.06. In the last 3 months the share price increased with 30.59%.
SYTA25.05%SIYATA MOBILE INC (NASDAQ:SYTA) rose 25.05% to $0.47 during Thursday's pre-market session. In the last month the stock lost 48.08%.
AVCT20.19%AMERICAN VIRTUAL CLOUD TECHN's (NASDAQ:AVCT) shares rose 20.19% to $0.26. Shareholders saw the stock price going 53.27% higher in the past month.
COSM19.06%COSMOS HOLDINGS INC's (NASDAQ:COSM) shares rose 19.06% to $0.28. In the last month the stock lost 36.6%.
BEAT17.72%HEARTBEAM INC's (NASDAQ:BEAT) shares rose 17.72% to $1.86 during Thursday's pre-market session. NASDAQ:BEAT seems to be recovering from a -16.4% loss in the previous session. A press release (HeartBeam Launches New Video Showcasing the HeartBeam AIMI™ and AIMIGo™ Technologies) was released two days ago.
EGIO13.95%EDGIO INC's (NASDAQ:EGIO) shares rose 13.95% to $3.43. Two days ago the company had a press release: Edgio Completes Week By Setting All-Time Traffic Record.
PSTV12.16%PLUS THERAPEUTICS INC's (NASDAQ:PSTV) shares rose 12.16% to $0.55. Shareholders saw the stock price going 36.04% lower in the past month.
CNXA10.64%CONNEXA SPORTS TECHNOLOGIES's (NASDAQ:CNXA) shares rose 10.64% to $0.52 during Thursday's pre-market session. In the last month the stock lost 53.0%.

For the full premarket gainers list go to our premarket gainers screener.

Pre-market losers

TickerChangeComment
SLNH-15.48%SOLUNA HOLDINGS INC's (NASDAQ:SLNH) shares fell 15.48% to $1.42 during Thursday's pre-market session. In the last month the stock lost 47.83%.
ADMP-13.73%ADAMIS PHARMACEUTICALS CORP's (NASDAQ:ADMP) stock price is declining with 13.73% to a price of $0.22. Yesterday's drop of -28.26% continued in today's pre-market session with another decline of 13.73%
AEMD-13.1%AETHLON MEDICAL INC's (NASDAQ:AEMD) stock price is declining with 13.1% to a price of $0.65. The stock is trading 34.39% lower than a month ago.
TOPS-12.4%TOP SHIPS INC's (NASDAQ:TOPS) shares fell 12.4% to $0.19. The stock is trading 29.7% lower than a month ago.
PULM-11.46%PULMATRIX INC's (NASDAQ:PULM) shares fell 11.46% to $3.4 during Thursday's pre-market session. Shareholders saw the stock price going 42.52% lower is the past 6 months.
SNAX-11.14%STRYVE FOODS INC-CLASS A's (NASDAQ:SNAX) stock price decreased by 11.14% to $0.48. The stock is trading 20.64% lower than a month ago.
SLDB-10.91%SOLID BIOSCIENCES INC's (NASDAQ:SLDB) shares fell 10.91% to $0.5 during Thursday's pre-market session. In the last month the share price dropped with 23.14%.
SLNG-10.41%STABILIS SOLUTIONS INC's (NASDAQ:SLNG) stock price decreased by 10.41% to $7.92. After yesterdays gain of 73.67%, it goes down with 10.41% in today's pre-market session.
EVAX-10.3%EVAXION BIOTECH A/S's (NASDAQ:EVAX) shares fell 10.3% to $2.09. Prices are quite volatile now: this is a reversal from yesterday's 22.63% gain.
KIND-9.24%NEXTDOOR HOLDINGS INC's (NYSE:KIND) stock price decreased by 9.24% to $2.85. The stock is trading 48.18% lower than 6 months ago.

To see the full list of premarket losers you can use our premarket losers screener.

Back

SPERO THERAPEUTICS INC

NASDAQ:SPRO (4/23/2024, 7:26:23 PM)

1.435

+0.03 (+2.14%)

SPRO News

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning!

News Imagea month ago - Spero Therapeutics, Inc.Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected...

News Image2 months ago - Spero Therapeutics, Inc.Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image2 months ago - Spero Therapeutics, Inc.Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image2 months ago - Spero Therapeutics, Inc.Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...

News Image3 months ago - Spero Therapeutics, Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image4 months ago - Spero Therapeutics, Inc.Spero Therapeutics Provides Corporate Update and 2024 Outlook

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients

News Image4 months ago - Spero Therapeutics, Inc.Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

$95 million in development milestones payable over two years, as part of GSK license agreement...

News Image6 months ago - Bragar Eagel & Squire, P.C.SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
SPRO Links
Follow us for more